Form 4 for VERA Vera Therapeutics, Inc.
Accepted 2022-11-17 00:00:00 ET · period of report 2022-11-16 · accession 0001209191-22-057513 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-11-17 | 2022-11-16 | VERA | Fordyce Marshall | Pres, CEO, Dir | M - OptEx | $2.85 | +65.2K | 246.3K | +36% | +$186.0K |
| DM | 2022-11-17 | 2022-11-16 | VERA | Fordyce Marshall | Pres, CEO, Dir | M - OptEx | $0.00 | -65.2K | 887.2K | -7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-11-16 | M | A | 5,153 | $2.32 | 186,303 | D | — | — | |
| 2 | Common | Class A Common Stock | 2022-11-16 | M | A | 60,000 | $2.90 | 246,303 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2022-11-16 | M | D | 5,153 | $0.00 | 516 | D | $2.32 · — to 2030-01-15 | 5,153 Class A Common Stock | (F1) 1/3 of the shares subject to the option vested on January 10, 2021, and 1/36 of the shares vest monthly thereafter. |
| 4 | Derivative | Stock Option (Right to Buy) | 2022-11-16 | M | D | 60,000 | $0.00 | 887,212 | D | $2.90 · — to 2030-12-15 | 60,000 Class A Common Stock | (F2) 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter. |